Urokinase is a white powder.
This product is mainly used for thrombolytic treatment of thromboembolic diseases. These included acute extensive pulmonary embolism, coronary artery embolization and myocardial infarction within 6-12 hours of chest pain, acute stage cerebral vascular embolization with symptoms shorter than 3-6 hours, retinal artery embolization, and other severe peripheral arterial embolization of ilio-femoral vein thrombosis. It is also used to prevent thrombus formation after artificial heart flap operation, and to keep the vascular intubation and the thoracic cavity and pericardial cavity drainage tube unobtrusive. The therapeutic effect of thrombolytic therapy should be maintained by subsequent heparin anticoagulation.
The goods can direct effects on endogenous fibrinolysis system into a fibrinolytic enzyme catalytic cracking fibrinolytic enzyme, which can not only degradation of fibrin clot, also can degrade fibrinogen in blood, and clotting factor Ⅴ and blood coagulation factor Ⅷ etc, so as to play a role of thrombolysis. The product has quick and good effect on the newly formed thrombus. The product can also improve the activity of vascular ADP enzyme, inhibit adp-induced platelet aggregation, and prevent thrombosis. After intravenous infusion, the fibrinolytic enzyme activity in the patients increased significantly. Several hours after discontinuation, fibrinolytic activity returned to its original level, but the reduction in plasma fibrin or fibrinogen levels and the increase in their degradation products lasted for 12-24 hours. The results showed that the thrombolytic effect was significantly correlated with the dosage and time window of administration. The toxicity was very low, and the lethal dose of intravenous injection of half of the mice was more than 1 million ius/kg body weight. There was no obvious antigenicity, teratogenicity, carcinogenicity or mutagenicity. There are few reports of anaphylaxis in clinical application. However, as the product increases the activity of fibrinolytic enzyme and reduces the unbound plasminogen and fibrinogen binding to fibrin in blood circulation, serious bleeding risk may occur.